AIMS/HYPOTHESIS: The peroxisome proliferator-activated receptor gamma coactivator 1-alpha protein, encoded by the PPARGC1A gene, transcriptionally activates a complex pathway of lipid and glucose metabolism and is expressed primarily in tissues of high metabolic activity such as liver, heart and exercising oxidative skeletal muscle fibre. Ppargc1a-null mice develop systemic dyslipidaemia and hepatic steatosis. In humans, NEFAs downregulate PPARGC1A expression in skeletal muscle. Furthermore, a common non-synonymous coding variant at PPARGC1A (Gly482Ser, rs8192678) is associated with decreased PPARGC1A mRNA levels and increased type 2 diabetes risk. MATERIALS AND METHODS: In a population-based sample of 691 healthy middle-aged Europids we assessed whether Gly482Ser is associated with levels of NEFA when fasting and in response to an oral glucose challenge. We also assessed the potential effect-modifying role of adipose tissue mass on these phenotypes. RESULTS: After adjustment for age, sex, fat mass and fat-free mass, the Ser482 allele associated with higher NEFA at 30 min and 2 h and with NEFA AUC (all values p<or=0.02). Furthermore, suggestive evidence of interaction between fat mass and Gly482Ser was observed for fasting NEFA (p=0.059). After stratification by level of obesity, genotype associations were observed in the obese for fasting NEFA (p=0.028) and NEFA at 30 min (p=0.013) and 2 h (p=0.002), and with NEFA AUC (p=0.005), but no significant associations were observed in lean individuals (all values p>0.6). CONCLUSIONS/ INTERPRETATION: Our observations indicate that NEFA clearance is blunted following a glucose load in carriers of the PPARCG1A Ser482 allele. This association is augmented by obesity.
AIMS/HYPOTHESIS: The peroxisome proliferator-activated receptor gamma coactivator 1-alpha protein, encoded by the PPARGC1A gene, transcriptionally activates a complex pathway of lipid and glucose metabolism and is expressed primarily in tissues of high metabolic activity such as liver, heart and exercising oxidative skeletal muscle fibre. Ppargc1a-null mice develop systemic dyslipidaemia and hepatic steatosis. In humans, NEFAs downregulate PPARGC1A expression in skeletal muscle. Furthermore, a common non-synonymous coding variant at PPARGC1A (Gly482Ser, rs8192678) is associated with decreased PPARGC1A mRNA levels and increased type 2 diabetes risk. MATERIALS AND METHODS: In a population-based sample of 691 healthy middle-aged Europids we assessed whether Gly482Ser is associated with levels of NEFA when fasting and in response to an oral glucose challenge. We also assessed the potential effect-modifying role of adipose tissue mass on these phenotypes. RESULTS: After adjustment for age, sex, fat mass and fat-free mass, the Ser482 allele associated with higher NEFA at 30 min and 2 h and with NEFA AUC (all values p<or=0.02). Furthermore, suggestive evidence of interaction between fat mass and Gly482Ser was observed for fasting NEFA (p=0.059). After stratification by level of obesity, genotype associations were observed in the obese for fasting NEFA (p=0.028) and NEFA at 30 min (p=0.013) and 2 h (p=0.002), and with NEFA AUC (p=0.005), but no significant associations were observed in lean individuals (all values p>0.6). CONCLUSIONS/ INTERPRETATION: Our observations indicate that NEFA clearance is blunted following a glucose load in carriers of the PPARCG1A Ser482 allele. This association is augmented by obesity.
Authors: I Barroso; J Luan; M S Sandhu; P W Franks; V Crowley; A J Schafer; S O'Rahilly; N J Wareham Journal: Diabetologia Date: 2006-01-25 Impact factor: 10.122
Authors: J Hoeks; M K C Hesselink; A P Russell; M Mensink; W H M Saris; R P Mensink; P Schrauwen Journal: Diabetologia Date: 2006-08-01 Impact factor: 10.122
Authors: Harald Esterbauer; Hannes Oberkofler; Veronika Linnemayr; Bernhard Iglseder; Margot Hedegger; Peter Wolfsgruber; Bernhard Paulweber; Gerd Fastner; Franz Krempler; Wolfgang Patsch Journal: Diabetes Date: 2002-04 Impact factor: 9.461
Authors: J Ek; G Andersen; S A Urhammer; P H Gaede; T Drivsholm; K Borch-Johnsen; T Hansen; O Pedersen Journal: Diabetologia Date: 2001-12 Impact factor: 10.122
Authors: R K Semple; V C Crowley; C P Sewter; M Laudes; C Christodoulides; R V Considine; A Vidal-Puig; S O'Rahilly Journal: Int J Obes Relat Metab Disord Date: 2004-01
Authors: Vamsi K Mootha; Cecilia M Lindgren; Karl-Fredrik Eriksson; Aravind Subramanian; Smita Sihag; Joseph Lehar; Pere Puigserver; Emma Carlsson; Martin Ridderstråle; Esa Laurila; Nicholas Houstis; Mark J Daly; Nick Patterson; Jill P Mesirov; Todd R Golub; Pablo Tamayo; Bruce Spiegelman; Eric S Lander; Joel N Hirschhorn; David Altshuler; Leif C Groop Journal: Nat Genet Date: 2003-07 Impact factor: 38.330
Authors: Inês Barroso; Jian'an Luan; Rita P S Middelberg; Anne-Helen Harding; Paul W Franks; Rupert W Jakes; D Clayton; Alan J Schafer; Stephen O'Rahilly; Nicholas J Wareham Journal: PLoS Biol Date: 2003-10-13 Impact factor: 8.029
Authors: Paul W Franks; Costas A Christophi; Kathleen A Jablonski; Liana K Billings; Linda M Delahanty; Edward S Horton; William C Knowler; Jose C Florez Journal: Diabetologia Date: 2013-12-07 Impact factor: 10.122
Authors: E C Brito; K S Vimaleswaran; S Brage; L B Andersen; L B Sardinha; N J Wareham; U Ekelund; R J F Loos; P W Franks Journal: Diabetologia Date: 2009-01-29 Impact factor: 10.122
Authors: Tatiana A Larkina; Anna L Sazanova; Kirill A Fomichev; Olga Y Barkova; Tadeusz Malewski; Kazimierz Jaszczak; Alexei A Sazanov Journal: J Appl Genet Date: 2010-12-16 Impact factor: 3.240
Authors: Karani Santhanakrishnan Vimaleswaran; Jian'an Luan; Gitte Andersen; Y Li Muller; Eleanor Wheeler; Ema C Brito; Stephen O'Rahilly; Oluf Pedersen; Leslie J Baier; William C Knowler; Inês Barroso; Nicholas J Wareham; Ruth J F Loos; Paul W Franks Journal: J Appl Physiol (1985) Date: 2008-05-08